Marking the latest development in the Illumina/Grail saga, on 3 September 2024, the CJEU annulled the General Court’s judgment and European Commission’s decisions allowing EU national competition authorities (NCAs) to review concentrations that fall below national (turnover) thresholds. In 2021, Illumina, a U.S. biotech company, sought to acquire Grail, a U.S. company developing tests for…